TC Biopharm (Holding) PLC (TCBP) late-stage biotherapeutics company that is primarily focused on discovering, manufacturing, and marketing the cellular therapies related to gamma-delta T cells for the cure of carcinoma and acute myeloid leukemia. The company utilizes an allogeneic method to successfully eradicate the tumors. The company is the pioneer in conducting phase 2 pivotal clinical trials in cancer. The product line of the company in Phase 2/3 trial is OmnImmune for acute myeloid leukemia and in Phase 1 trial for ImmuniStim to treat COVID-19 patients. The company is also maintaining a vigorous pipeline for futuristic indications in tumors.
The price of TCBP stock in the regular trading on March 8, 2022, with an incline of 2.53% was $0.96. Its price further flew by 40.91% at the last check of the premarket session on March 9, 2022.
TCBP: Events and Happenings
On March 8, 2022, TCBP announced the optimistic interim results for its Phase 1/2 human trials assessing the efficacy, and safety data of OmnImmune or TCB-002 used in treating AML.
TCBP: CEO Comments
Speaking at this momentous occasion, TCBP CEO Bryan Kobel stated that the company is pleased to receive hopeful results demonstrating OmnImmune as tolerable among the patients. He further added that the outcomes underscore TCB-002 potential to become a worthwhile AML treatment shortly.
On March 2, 2022, TCBP reported hosting a corporate call on March 8, 2022. On February 15, 2022, TCBP updated on the closure of its prior announced preliminary public offering of 4,117,648 ADS and warrants for the acquisition of approximately 8,235,296 ADS. The company received total net proceeds worth $17.5 million from the offering. On February 11, 2022, TCBP was informed about the commencement of its ADS or ordinary shares on the Nasdaq under the ticker ‘TCBP.
Conclusion
The company’s stock is 54% down from the beginning of trading on NASDAQ on February 11, 2022. Its stock rocketed in the premarket session today as the company announced the positive topline results from its TCB-002 clinical trials. It is one of the biggest achievements of the company in terms of grounding its position in the biotech industry.
